Daniel P. Petrylak, MD, presented “ESMO: Astellas, Seattle Genetics’ Keytruda Combo Shrinks 71% of Bladder Cancers” for the Grand Rounds in Urology audience in October 2019.

How to cite: Petrylak, Daniel P. “ESMO: Astellas, Seattle Genetics’ Keytruda Combo Shrinks 71% of Bladder Cancers” December, 2019. Accessed Jan 2020. https://grandroundsinurology.com/esmo-astellas-seattle-genetics-keytruda-combo-shrinks-71-of-bladder-cancers/

ESMO: Astellas, Seattle Genetics’ Keytruda Combo Shrinks 71% of Bladder Cancers – Summary:

E. David Crawford, MD, interviews Daniel P. Petrylak, MD, about a Phase 1b trial of cisplatin-ineligible bladder cancer patients given a combination of pembrolizumab and enfortumab vedotin that resulted in a 71% response rate. Dr. Petrylak details what makes a patient cisplatin-ineligible, discusses the partial and complete responses to the drug combination, and lays out future plans to study the efficacy of this therapy in the treatment of urothelial cancer.